Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | terminated | Phase 3 | 38 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 8 | AkesoINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies |
| terminated |
| Phase 1 |
| 87 |
| Atreca, Inc.INDUSTRY |
| 1 |
| Dec 29, 2023 |
| clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT00176631 | Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT00633087 | A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer(2-Deoxyglucose) | terminated | Phase 1 / Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | terminated | Phase 1 | 14 | BayerINDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03837353 | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | terminated | Phase 1 / Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | terminated | Phase 1 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | terminated | Early Phase 1 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab | terminated | N/A | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03550040 | 3D Versus Robot Assisted Laparoscopic Prostatectomy. | terminated | N/A | 155 | Tampere University HospitalOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03944902 | CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients(BRCA) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02432690 | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | terminated | Phase 2 | 13 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05910697 | Clinical Utility of MyProstateScore 2.0 P2 | terminated | N/A | 142 | Qure Healthcare, LLCINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | terminated | Phase 2 | 26 | University of MiamiOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05332483 | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer(MA-EEC) | terminated | Phase 1 | 5 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03619655 | Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer(AXLerate-OC) | terminated | Phase 3 | 366 | Aravive, Inc.INDUSTRY | 11 | Oct 30, 2023 | clinicaltrials |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | terminated | Phase 2 | 31 | Albert Einstein College of MedicineOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery | terminated | Phase 4 | 21 | University of Missouri-ColumbiaOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | terminated | N/A | 186 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03180398 | Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients | terminated | N/A | 9 | Henry Ford Health SystemOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04598321 | BrUOG 390: Neoadjuvant Treatment With Talazoparib | terminated | Phase 1 | 1 | Brown UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04511026 | Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer | terminated | Phase 2 | 6 | Stanford UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer(UPGRADE) | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01420861 | GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer | terminated | Phase 2 | 18 | GTxINDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04891185 | Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer(VIPIDO) | terminated | Phase 2 | 14 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT00006099 | Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer | terminated | Phase 1 | 1 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00769652 | Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer | terminated | N/A | 8 | Rutgers, The State University of New JerseyOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01377389 | Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 80 | Veru Inc.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01076400 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | terminated | Phase 1 / Phase 2 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 18, 2023 | clinicaltrials |
| NCT00176644 | Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00483561 | Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 26 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03302156 | PSMA PET and MRI in Gynecological Cancers | terminated | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System(CHARTER) | terminated | — | 9 | Angle plcINDUSTRY | 1 | Sep 5, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2024source: clinicaltrials